Purdue Pharma taps financial restructuring firm; White House wants opioid-production cut; NYU to make med school free.
CDC estimates 72,000 died of drug overdoses in 2017; Genentech to lay off 200-plus employees; Pfizer invests up to $425 million in BioNTech.
Alphabet invests more in Oscar; ViiV's HIV injection proves effective; Gilead's chief medical officer departs in latest executive exit.
Icahn drops bid to stop Cigna-Express Scripts tie-up; Bayer joins Evotec-Haplogen partnership to find COPD treatments; Orchard raises $150 million in Series C funding.
Bayer shares fall after Monsanto weedkiller judgment; FDA approves first birth-control app to be marketed as contraception method; Regulators okay landmark RNAi-based therapy.
FDA approves record number of generics in July; Trump drug-pricing policies may be hurting generic makers; Justice Department joins opioid lawsuit.
Rite Aid, Albertsons call off merger; AMA disapproves of CVS-Aetna deal; FDA signs off on first generic drug for CGT designation.
Trump promises move to lower drug prices; CVS, Novo Nordisk beat earnings predictions; AstraZeneca settles two suits with Texas for $110 million.
Icahn asks Cigna investors to reject $54 billion Express Scripts deal; FDA changes opioid treatment evaluation; GSK names CFO.
Regeneron invests $100 million in bluebird; Boehringer Ingelheim starts cystic fibrosis coalition; FDA rejects Pain Therapeutics' application to sell Remoxy.
Allergan sues Pfizer to cover costs of opioid lawsuits; Drug companies donate millions to areas hit by the opioid crisis; Mayo Clinic: Opioid prescriptions not decreasing.
Lead Tecentriq scientist resigns; Apple hires for on-site health clinic; Novo launches DTC diabetes campaign.
Pfizer CEO says rebates to go away; Ispos to acquire four GfK research divisions; Sanofi promises to return to growth in 2H 2018.
Pfizer lowers full-year forecast; Bayer to sell prescription dermatology brands to Leo; behind July's healthcare agency M&A boom.
Study: Few patients use price-comparison tools to shop for lower-limb MRIs; Ascletis raises $400 million in Hong Kong IPO; California bucks trend on maternal death rates.
AstraZeneca promises to not raise drug prices this year; EHR adoption could lower hospital death rates: study; Roche's new drugs drive earnings.
Alzheimer's drug slows cognitive decline; Gilead CEO to leave; Amgen migraine drug face difficulties with insurers.
Full-page Purdue print ad amended; GSK partners with 23andMe; AbbVie's endometriosis drug to cost more than $10,000 per year.
Commercial chief to exit Bristol-Myers Squibb; Study: Wal-Mart $4 prescription plan a more affordable option for some Medicare patients; Trump administration pushes back on antibiotic use on farm animals.
Bayer to stop selling Essure; FDA approves Agios' leukemia treatment; Investor lawsuit targets Theranos.
More drugmakers vow to halt price increases; FDA considers allowing imported drugs in some cases; Trump administration examines rebates.
Healthcare decline weighs on Publicis Q2 earnings; Gottlieb releases biosimilar plan; Roche's lung cancer treatment shows positive results.
Novartis voluntarily halts price increases; Shkreli's former company considers name change; FDA issues guidance to modernize electronic health data in trials.
J&J beats expectations on Q2 earnings; AbbVie, Mylan sign U.S. license deal for Humira; Roche's new flu drug meets endpoints.
MM&M Awards shortlist revealed; FDA approves first smallpox treatment; Another way Amazon could drive down healthcare costs.
Senate probe finds more contact between Novartis, Cohen; J&J ordered to pay $4.7 billion in talc lawsuit; FDA warns Arog about misleading promotional material.
Pfizer announces restructuring hours after about face on price hikes; Feds to slash funding for ACA "navigators"; Study finds rural states lag in combating heart disease.
CMS ends plan to make Novartis cancer treatment cheaper; Trump calls out Pfizer on Twitter for price hikes; News organizations sue to get federal opioid data.
The most comprehensive look at the pharma and healthcare agency world from MM&M.
Positive Alzheimer's trial sends Biogen shares surging; A year after crisis, analysts come around to AstraZeneca stock; Ironwood cuts 40 jobs ahead of split.